Background: Pneumococcal disease continues to cause substantial morbidity and
Introduction
Streptococcus pneumoniae is the leading cause of bacterial pneumonia and bacterial meningitis in the United States, resulting in 175,000 hospitalizations and 7,000 to 12,000 deaths annually. Groups with the highest incidence of pneumococcal infection include the very young, the elderly, persons who are immunocompromised, smokers, and certain other demographic groups (2, 8). In persons 65 years or older, the incidence of invasive pneumococcal disease (IPD) is around 50 per 100,000 per year, and is associated with a case fatality rate of 20% whereas among those aged 85 years or older, the fatality rate increases to 40% (2, 34).
The Advisory Committee on Immunization Practices recommends vaccinating all adults aged 65 years or older with the 23-valent pneumococcal polysaccharide vaccine (PPV).
One-time revaccination for this age group is also recommended if they received their first dose ≥ 5 years previously and before the age of 65 years (6). A recent meta-analysis provided evidence supporting the recommendation for PPV to prevent IPD in adults.
However, it did not provide compelling evidence to support the routine use of PPV to prevent all-cause pneumonia or mortality (15) . In addition, significant protection against IPD seems to be lost as early as 3-5 years after vaccination in persons older than 65 years (28, 29) .
A common surrogate for antibody-mediated protection is the measurement of postvaccination IgG antibody to capsular polysaccharides contained in PPV. Validation of this measure may be disputed given the fact that even adequate IgG concentrations in the elderly may have significant reductions in antibody functional activity to pneumococcal on January 11, 2018 by guest http://cvi.asm.org/ Downloaded from polysaccharide antigens (25) . Molecular characterization of the immune response to pneumococcal polysaccharides is seldom performed in clinical vaccine studies (24) ; however, there is a large body of literature on this subject (3, 5, 7, 22, 38) . Recent studies have demonstrated that PPV stimulates an increased expression of variable region heavy chain family 3 (V H 3) genes in peripheral B cells from immunocompetent subjects, yielding serum polysaccharide-specific antibodies and/or B-cells that express V H 3 (1, 7, 32, 33) . V H 3 responses may also correlate with functional activity of anti-pneumococcal antibodies (3).
Previous studies on gene expression of the B-cell repertoire of the total circulating B-cell population demonstrated a shift toward V H 4 and V H 1 expression in aging humans compared with predominant V H 3 expression in young subjects (35) . This repertoire shift has been postulated as a possible mechanism of decreased pneumococcal anti-capsular antibody function in older populations. In this regard, a preliminary report (30) found a lower expression of V H 3-idiotypic antibody responses to capsular polysaccharides from serotype 4 but not serotype 14 in the elderly when compared with young individuals. A subsequent study (11) of the V H gene repertoire of human peripheral B cells specific for these two capsular polysaccharides (4 and 14) revealed that the response in both age groups was dominated by the V H 3 gene family (> 90%). The V H 1, V H 4, and V H 5 gene families were also isolated from both groups but they constituted <10% of the total heavy chain repertoire. Given the attractiveness of the study of V H 3-idiotypic antibody responses to assess the immunogenicity of pneumococcal polysaccharide antigens and the need of further studies on its role in aging, we evaluated IgG and V H 3-idiotypic antibody on January 11, 2018 by guest http://cvi.asm.org/ Downloaded from responses after administration of PPV in sera from a subset of vaccine-naive and revaccinated middle-aged and elderly subjects enrolled in a pneumococcal vaccine clinical trial (19) . Study subjects were participants of a multisite study evaluating the safety and immunogenicity of primary vaccination and revaccination with PPV and were recruited and vaccinated at the Houston Veterans Affairs Medical Center under a protocol that was approved by the Institutional Review Board, Baylor College of Medicine, as previously described (19) . Subjects were included based on the availability of sera. Re-immunized subjects had received the initial vaccine 3-5 years previously as part of their routine medical care. Blood samples were obtained before and 4 weeks after initial vaccination or revaccination. Serum was separated from whole blood samples by centrifugation and stored at -70˚C until analyzed. For the current study, all samples were re-assayed as 23F were determined by a sandwich ELISA, as it has been described elsewhere (36) . We decided to study four representative serotypes that are reported to cause a significant number of cases of IPD among middle-aged and elderly persons the United States (37).
Material and Methods

Studies
Serum samples were pre-absorbed with 5 µg/mL pneumococcal cell-wall polysaccharide (CWPS; Statens Seruminstitut) and 5 µg/mL type 22F CPS (ATCC) for 30 min at room temperature following the World Health Organization guidance protocol for pneumococcal antibody ELISA (36) (this methodology differs from the one described for the main study which used serotypes 25 and 72 for adsorption) (19) . Dilutions of a laboratory reference serum (Pool 89-SF; Food and Drug Administration) were included on every ELISA plate. All serum samples from each individual were studied concurrently.
Idiotype expression of antibodies: The V H 3 expression of antibodies to the pneumococcal vaccine in pre-and post-vaccination sera was determined by ELISA, as described 
Results
IgG antibody response: GMC of IgG to individual pneumococcal capsular polysaccharides (serotypes) according to age group and vaccination status are shown in Table 1 . Pre-and post-vaccination IgG levels were similar between middle-aged and elderly groups. When stratified by vaccine status, pre-vaccination IgG level was higher in previously immunized subjects than in vaccine-naive in both groups and for all serotypes; however this difference was statistically significant only for serotype 14 in both middleaged and elderly groups (P < 0.03 for both comparisons). Despite these differences in pre-vaccine levels, post-vaccination IgG levels were similar in all subgroups. Middleaged and elderly groups showed significant increases (within-group comparisons) in their IgG levels to all four serotypes (P < 0.01 for all comparisons). Stratified analysis also on January 11, 2018 by guest http://cvi.asm.org/ Downloaded from showed significant IgG increases in all subgroups to all serotypes (P < 0.05 for all comparisons).
V H 3-idiotype antibody response: Pre-and post-vaccination V H 3 levels were similar between middle-aged and elderly groups even after stratification by vaccine status. Both groups showed significant increases (within-group comparisons) in their V H 3 antibody titers after vaccination with PPV (P < 0.01 for both comparisons) ( Table 2 ). Stratified analysis also showed significant increases in V H 3 levels in all subgroups (P < 0.03 for all comparisons) (Figure 1 ). Comparable proportions of middle-aged and elderly patients experience two-fold increases in V H 3 antibody titers (54.8% and 45.7%, respectively, P = 0.46). Although not a statistically significant difference, a higher proportion of vaccinenaïve subject had 2-fold increases in V H 3 antibody titers when compared to revaccinated groups (75% and 55% vs. 33. 3% and 33.3% for middle-aged and elderly patients, respectively) (P = 0.06).
Correlations: V H 3-idiotypic antibody responses were correlated with IgG responses to serotypes 14 (r= 0.36, P = 0.03) and 23F (r = 0.45, P < 0.01). No significant correlations were observed for the other two serotypes.
Discussion
In our study, age did not influence the magnitude or the quality of the antibody responses elicited by the pneumococcal polysaccharide vaccine among either vaccine-naïve or previously immunized subjects. This was evidenced by similar post-vaccination IgG and V H 3 levels in middle-aged and elderly groups even after stratifying by prior vaccine on January 11, 2018 by guest http://cvi.asm.org/ Downloaded from status. Furthermore, our study showed similar proportions of healthy elderly and middleaged subjects experiencing two-fold increases in V H 3 antibody titers after pneumococcal polysaccharide vaccine.
Several previous studies had shown a similar IgG antibody response to pneumococcal polysaccharides in elderly individuals compared with their younger counterparts (4, 17, 26, 27); however, these levels do not always accurately correlate with the functional antibody activity (25) nor with protection against pneumococcal disease (20) . In addition, other studies have suggested that humoral responses among elderly subjects correlate better with their functional status than with their chronological age (4, 23). Our patients were all ambulatory subjects without concomitant debilitating acute or chronic illness, who were expected to survive for 5 years after study enrollment (19) . Therefore our results on V H 3 response among ambulatory elderly subjects may not be extrapolated to elderly frail patients.
As a vaccine composed of polysaccharide antigens, PPV induces a T-cell-independent response and thus, an anamnestic response (i.e., booster) is unlikely (31) . Immunologic tolerance or hyporesponsiveness induced by prior polysaccharide antigen exposure constitutes a potential concern when considering revaccination with PPV (9, 21).
Although pre-vaccination IgG levels to some serotypes were higher in previously immunized subjects, post-vaccination levels actually reached similar levels in all subgroups. However, as a result of higher pre-vaccination titers, a lower proportion of revaccinated subjects achieve a 2-fold response. Our results are concurrent with those of the main study (19) . In addition, in a different substudy, Manoff and collaborators on January 11, 2018 by guest http://cvi.asm.org/ Downloaded from showed that revaccination of adults aged ≥65 years was comparable to primary vaccination for inducing elevated and persistent functional (measured by opsonophagocytic assay) specific anticapsular antibodies; in this study the results of the functional assays correlated with the IgG antibody responses (14) . These results agree with those of earlier studies that revaccination elicits a significant response but not of greater intensity than that to the initial vaccination (10, 14, 16, 34); and most importantly, it indicates that any possible difference initially observed in the antibody response of revaccinated and vaccine-naïve subjects do not persist over time. Among HIV infected patients on HAART, the V H 3 response to polysaccharide antigens after revaccination was similar to that of initial vaccination (32) . Similarly, our data indicate that adults aged 50-65 years or >65 do mount a significant serotype-and V H 3-specific antibody response to revaccination with PPV. However, we have not evaluated the functional activity of the V H 3 specific antibodies, and correlation of V H 3 specific antibodies with function, although supported by one small study (3), continues to be speculative.
We found a linear correlation between V H 3 antibodies to the whole vaccine and IgG responses to two serotypes (14 and 23F). In a previous study (1) utilizing the same assay, antibodies to capsular polysaccharides of serotypes 3, 6B and 14 did not yield V H 3 determinants recognized by the D12 monoclonal antibody. The prior study evaluated the antibody response among a younger group of subjects. It is possible that there is a differential expression of V H 3 epitopes among different serotypes that is influenced by age [11, 29] . 
